Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Switzerland Daily Monitor.
Press releases published on April 9, 2025
21Shares Files Form S-1 for Dogecoin ETF in the U.S.
GlobeNewswire
·
April 9, 2025
NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- 21Shares has filed an S-1 registration statement with the U.S. Securities and Exchange Commission (“SEC”) for a Dogecoin exchange traded fund (“ETF”). The launch of the 21Shares Dogecoin ETF is pending …
21Shares Forms Exclusive Partnership with the House of Doge to Launch Dogecoin ETPs Globally
GlobeNewswire
·
April 9, 2025
NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- 21Shares AG (“21Shares”), a leading global issuer of cryptocurrency exchange-traded products (“ETPs”), has formed an exclusive partnership with the House of Doge to launch the only Dogecoin ETPs endorsed by the …
Emerald Technology Ventures Celebrates Four Portfolio Companies in TIME’s World’s Top GreenTech Companies of 2025
GlobeNewswire
·
April 9, 2025
ZURICH, April 09, 2025 (GLOBE NEWSWIRE) -- Emerald Technology Ventures, a global pioneer in venture capital dedicated to sustainable technologies and industrial innovation, has announced that four of its portfolio companies have been named to TIME magazine …
XRP News: XploraDEX Hits Soft Cap as $XPL Presale Enters Final Phase, Limited Time Left Before Hard Cap
GlobeNewswire
·
April 9, 2025
ZURICH, April 09, 2025 (GLOBE NEWSWIRE) -- The first AI-powered decentralized exchange built on the XRP Ledger, XploraDEX, has officially achieved its soft cap fundraising goal, marking a major milestone in one of the most talked-about DeFi token sales of …
Cytosurge Appoints Magid Haddouchi as Chief Commercial Officer
GlobeNewswire
·
April 9, 2025
ZURICH, Switzerland, April 09, 2025 (GLOBE NEWSWIRE) -- Cytosurge AG, a leading biotech company in single-cell manipulation and cell engineering solutions, announces the appointment of Magid Haddouchi, PhD, as its new Chief Commercial Officer (CCO), …
The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension
GlobeNewswire
·
April 9, 2025
Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria in Black patients with confirmed resistant hypertension Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX …
US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement
GlobeNewswire
·
April 9, 2025
Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX: IDIA) today announced that the US Food …